The Valley Desk

Clinical trial reportInvestigational new drugsPublished

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Investigational new drugs
Published
Subject terms
Humans; Neoplasms; Antineoplastic Agents, Alkylating; Maximum Tolerated Dose; Dose-Response Relationship, Drug; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male; DNA damage
PubMed ID
42410111
Added to directory
Source checked

Report a correction or request removal